(2000; 140 pages) [French] [Spanish]
Drafts of this document at different stages of elaboration have been reviewed by: J. H. Reichman (Vanderbilt University, USA), Trevor Cook (United Kingdom), B.K. Keayla (India), and Ian Roberts (South Africa). Comments were also made by R. Kaukab (South Centre), S. Zarrilli (UNCTAD), B.L. Das (India), James Love (Consumer Project on Technology, Washington D.C.) and Bas van der Heide (Health Action International).
A preliminary presentation and discussion of an earlier version of the text was made in a parallel meeting to the WTO Ministerial Meeting in Seattle in December 1999. It was also reviewed by an expert group, co-sponsored by the Department of Essential Drugs of the World Health Organization and the Rockefeller Foundation. The members of the expert group which met on 12 May 2000 in New York, were: Sakiko Fukuda-Parr, Director, Human Development Report Office, United Nations Development Programme; Richard O. Laing, Associate Professor of International Health, Boston University School of Public Health; Frederick M. Abbott, Visiting Professor of Law, University of California at Berkeley School of Law; Joan Archer and Ruth Gana Okediji, Technical Co-operation for Developing Countries Programme, United Nations Development Programme; Jayashree Watal, Institute of International Economics, Washington D.C.; and German Velasquez, Coordinator, Drug Action Programme, Department of Essential Drugs and Medicines Policy, World Health Organization.
The author is grateful for their valuable comments and inputs, and also for the support from the Rockefeller Foundation for the preparation of this document.
Any views expressed are the views of the author and do not necessarily reflect the views of the Rockefeller Foundation or of the World Health Organization. The author is solely responsible for this final text.
This document has been edited by Robert Weissman.